5.84
price up icon0.34%   0.02
pre-market  Vorhandelsmarkt:  6.27   0.43   +7.36%
loading
Schlusskurs vom Vortag:
$5.82
Offen:
$5.75
24-Stunden-Volumen:
825.78K
Relative Volume:
0.67
Marktkapitalisierung:
$299.65M
Einnahmen:
$3.64M
Nettoeinkommen (Verlust:
$-87.37M
KGV:
-1.4209
EPS:
-4.11
Netto-Cashflow:
$-86.46M
1W Leistung:
-8.75%
1M Leistung:
+4.38%
6M Leistung:
+100.69%
1J Leistung:
-49.31%
1-Tages-Spanne:
Value
$5.4601
$6.09
1-Wochen-Bereich:
Value
$5.4601
$6.89
52-Wochen-Spanne:
Value
$2.10
$13.52

Verastem Inc Stock (VSTM) Company Profile

Name
Firmenname
Verastem Inc
Name
Telefon
(781) 292-4200
Name
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Name
Mitarbeiter
0
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
VSTM's Discussions on Twitter

Vergleichen Sie VSTM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VSTM
Verastem Inc
5.84 299.65M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-24 Bestätigt H.C. Wainwright Buy
2024-12-31 Bestätigt BTIG Research Buy
2024-09-30 Eingeleitet Guggenheim Buy
2023-11-21 Fortgesetzt BTIG Research Buy
2023-09-27 Eingeleitet B. Riley Securities Buy
2023-06-15 Hochstufung Mizuho Neutral → Buy
2022-09-07 Fortgesetzt Alliance Global Partners Buy
2022-04-29 Fortgesetzt Cantor Fitzgerald Overweight
2022-04-14 Eingeleitet RBC Capital Mkts Outperform
2022-03-09 Eingeleitet Truist Buy
2021-07-01 Eingeleitet Alliance Global Partners Buy
2021-05-24 Hochstufung BTIG Research Neutral → Buy
2019-06-20 Herabstufung BTIG Research Buy → Neutral
2019-05-10 Herabstufung Raymond James Outperform → Mkt Perform
2018-07-13 Eingeleitet BTIG Research Buy
2018-05-02 Eingeleitet Seaport Global Securities Buy
2018-03-08 Eingeleitet B. Riley FBR, Inc. Buy
2017-09-07 Bestätigt H.C. Wainwright Buy
2017-04-13 Eingeleitet Oppenheimer Outperform
2017-03-24 Bestätigt H.C. Wainwright Buy
2015-09-29 Herabstufung Cantor Fitzgerald Buy → Hold
2015-09-29 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 Herabstufung Jefferies Buy → Hold
2015-09-29 Herabstufung Raymond James Strong Buy → Outperform
2015-09-28 Herabstufung Mizuho Buy → Neutral
2015-09-28 Herabstufung ROTH Capital Buy → Neutral
2015-09-09 Eingeleitet Raymond James Strong Buy
2015-05-12 Bestätigt UBS Buy
2015-04-08 Eingeleitet H.C. Wainwright Buy
2015-01-23 Bestätigt ROTH Capital Buy
2014-07-08 Fortgesetzt Oppenheimer Perform
2014-02-11 Eingeleitet Mizuho Buy
Alle ansehen

Verastem Inc Aktie (VSTM) Neueste Nachrichten

pulisher
Apr 02, 2025

Verastem Oncology Reports Progress in Cancer Treatments - TipRanks

Apr 02, 2025
pulisher
Mar 28, 2025

Verastem (NASDAQ:VSTM) Upgraded at StockNews.com - MarketBeat

Mar 28, 2025
pulisher
Mar 27, 2025

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 25, 2025

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Revolutionary Cancer Drug Achieves Complete Response in Colorectal Cancer Study - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Verastem CFO Daniel Calkins sells shares worth $630 - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Verastem CFO Daniel Calkins sells shares worth $630 By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

H.C. Wainwright lifts Verastem stock price target to $10 By Investing.com - Investing.com Canada

Mar 24, 2025
pulisher
Mar 24, 2025

Guggenheim lifts Verastem stock target to $14, maintains buy By Investing.com - Investing.com Canada

Mar 24, 2025
pulisher
Mar 24, 2025

H.C. Wainwright lifts Verastem stock price target to $10 - Investing.com India

Mar 24, 2025
pulisher
Mar 23, 2025

Royal Bank of Canada Lowers Verastem (NASDAQ:VSTM) Price Target to $14.00 - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating -March 21, 2025 at 08:40 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

BTIG maintains $20 target, Buy rating on Verastem stock By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Verastem: Q4 Earnings Snapshot - Midland Daily News

Mar 21, 2025
pulisher
Mar 20, 2025

Verastem director Brian Stuglik sells shares worth $4,121 By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Unveils Strategic Plans in New Presentation - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Inc. (VSTM) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - Bluefield Daily Telegraph

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem director Robert Gagnon sells shares worth $1,973 By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Verastem CEO sells shares worth $1,695 By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Verastem director Robert Gagnon sells shares worth $1,973 - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Verastem director Brian Stuglik sells shares worth $4,121 - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Verastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Mar 18, 2025
pulisher
Mar 14, 2025

Verastem Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView

Mar 14, 2025
pulisher
Mar 13, 2025

Verastem to Present at Keystone Symposia on PI3 Kinase - AOL.com

Mar 13, 2025
pulisher
Mar 11, 2025

Verastem: Upcoming PDUFA, But I Remain Cautious (NASDAQ:VSTM) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Acquires 10,352 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World

Mar 11, 2025
pulisher
Mar 08, 2025

Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve

Mar 08, 2025
pulisher
Mar 08, 2025

Why the Global Cancer Market Could Surpass $900 Billion—And the Stocks Leading the Charge - Morningstar

Mar 08, 2025
pulisher
Mar 06, 2025

Verastem (VSTM) Expected to Announce Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Objective long/short (VSTM) Report - Stock Traders Daily

Mar 06, 2025
pulisher
Mar 05, 2025

Verastem Inc (NASDAQ: VSTM) Stock Forecast: Bearish Expectations Portend -120.34% Downside In 2025 - Stocks Register

Mar 05, 2025
pulisher
Mar 04, 2025

Verastem (NASDAQ:VSTM) Stock Price Passes Above 200 Day Moving Average – Should You Sell? - Defense World

Mar 04, 2025
pulisher
Feb 23, 2025

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of “Buy” by Brokerages - Defense World

Feb 23, 2025
pulisher
Feb 20, 2025

Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Cancer - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Business Wire

Feb 20, 2025
pulisher
Feb 19, 2025

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN

Feb 19, 2025
pulisher
Feb 13, 2025

When the Price of (VSTM) Talks, People Listen - Stock Traders Daily

Feb 13, 2025
pulisher
Feb 10, 2025

Financial Snapshot: Analyzing Verastem Inc (VSTM)’s Key Ratio Metrics - The Dwinnex

Feb 10, 2025
pulisher
Feb 08, 2025

Verastem Inc (NASDAQ: VSTM) Shares Fall By -4.77 Percent In The Past Week, But How Long Will It Last? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 06, 2025

The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News

Feb 06, 2025

Finanzdaten der Verastem Inc-Aktie (VSTM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Kapitalisierung:     |  Volumen (24h):